Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings

Abbott (ABT) reported $11.37 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.9%. EPS of $1.30 for the same period compares to $1.21 a year ago.The reported revenue represents a surprise of -0.24% over the Zacks Consensus Estimate of $11.4 billion. With the consensus EPS estimate being $1.30, the company has not delivered EPS surprise.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net sales- Nutrition- U.S.: $888 million versus the five-analyst average estimate of $966.71 million. The reported number represents a year-over-year change of -6.5%.Geographic Revenue- International: $7.07 billion compared to the $7.02 billion average estimate based on five analysts. The reported number represents a change of +9.9% year over year.Geographic Revenue- U.S.: $4.3 billion versus $4.38 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.Net sales- Diagnostics- International: $1.37 billion versus $1.4 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.Net sales- Nutrition: $2.15 billion versus $2.2 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.Net sales- Medical Devices- Diabetes Care: $2.06 billion versus $2.04 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +19.3% change.Net sales- Diagnostics: $2.25 billion versus $2.31 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.Net sales- Established Pharmaceuticals: $1.51 billion versus the six-analyst average estimate of $1.53 billion. The reported number represents a year-over-year change of +7.5%.Net sales- Medical Devices- Vascular- Total: $745 million versus $738.18 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.Net sales- Medical Devices- Neuromodulation- Total: $254 million compared to the $247.47 million average estimate based on five analysts. The reported number represents a change of +7.6% year over year.Net sales- Medical Devices- Structural Heart- Total: $635 million compared to the $634.17 million average estimate based on five analysts. The reported number represents a change of +13.8% year over year.Net sales- Medical Devices- Heart Failure- Total: $366 million versus $359.31 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.7% change.View all Key Company Metrics for Abbott here>>>Shares of Abbott have returned +0.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks